ID: ALA1241726

Max Phase: Preclinical

Molecular Formula: C16H20ClN3O

Molecular Weight: 305.81

Molecule Type: Small molecule

Representations

Canonical SMILES:  Clc1ccc2c(NCCCN3CCOCC3)ccnc2c1

Standard InChI:  InChI=1S/C16H20ClN3O/c17-13-2-3-14-15(4-6-19-16(14)12-13)18-5-1-7-20-8-10-21-11-9-20/h2-4,6,12H,1,5,7-11H2,(H,18,19)

Standard InChI Key:  YXFRGFRPDJRMHG-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 305.81

Molecular Weight (Monoisotopic): 305.1295

AlogP: 3.02

#Rotatable Bonds: 5

Polar Surface Area: 37.39

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 7.62

CX LogP: 2.07

CX LogD: 1.56

Aromatic Rings: 2

Heavy Atoms: 21

QED Weighted: 0.86

Np Likeness Score: -1.85

References

1. Solomon VR, Hu C, Lee H..  (2010)  Design and synthesis of chloroquine analogs with anti-breast cancer property.,  45  (9): [PMID:20561720] [10.1016/j.ejmech.2010.05.046]

2. Braga SF, Martins LC, da Silva EB, Sales Júnior PA, Murta SM, Romanha AJ, Soh WT, Brandstetter H, Ferreira RS, de Oliveira RB..  (2017)  Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification.,  25  (6): [PMID:28215783] [10.1016/j.bmc.2017.02.009]

3. Rocha DA, Silva EB, Fortes IS, Lopes MS, Ferreira RS, Andrade SF..  (2018)  Synthesis and structure-activity relationship studies of cruzain and rhodesain inhibitors.,  157  [PMID:30282318] [10.1016/j.ejmech.2018.08.079]

Source

Source(1):

• Scientific Literature